Daily oral PCSK9 drug could make powerful heart protection easier to access, a meaningful shift for prevention, healthspan and longevity.
True progress in medicine is measured by how little it demands of the person it’s meant to save. Breakthroughs aren’t just about adding years to a life, but about removing the “patient” from the person.
That may be the story behind enlicitide, an experimental once-daily pill that, in a large phase 3 clinical trial, cut low-density lipoprotein (LDL) cholesterol, often called “bad” cholesterol, by as much as 60%.
Published in The New England Journal of Medicine, the study points to something deceptively simple but potentially powerful: bringing one of the most effective cholesterol-lowering strategies out of the syringe and into a pill bottle [1].
This is relevant for longevity, not because cholesterol is a glamorous topic – it is not – but because cardiovascular disease remains one of the biggest barriers to living longer and living better. It is difficult to talk seriously about healthspan while ignoring the slow wear and tear happening inside the arteries.
LDL cholesterol has been one of medicine’s clearest villains for decades. When levels stay high, these particles can settle on the walls of arteries and gradually build up into plaque, like grease clogging a pipe over time. The damage is often quiet until it is not: a heart attack, a stroke or the kind of event that can instantly redraw the rest of a person’s life. That is why lowering LDL has remained one of the most reliable strategies in preventive medicine.
Yet, in the real world, many patients still do not hit their targets.
Dr Ann Marie Navar, a cardiologist and associate professor at UT Southwestern Medical Center, noted that fewer than half of patients with established atherosclerotic cardiovascular disease are meeting their LDL cholesterol targets. She suggested that a highly effective oral therapy could significantly enhance the medical community’s capacity to prevent heart attacks and strokes “on a population level [2].”
What makes this pill different
Enlicitide targets PCSK9, a protein involved in the body’s cholesterol-clearing system. Think of the liver as the body’s cleanup crew for LDL cholesterol. It uses receptors, the tiny catchers on liver cells, to pull LDL out of the bloodstream. PCSK9 gets in the way by reducing the number of those catchers. Less cleanup means more cholesterol circulating, where it can do harm.
Drugs that block PCSK9 are not new. Injectable versions already exist and are known to be highly effective, with some lowering LDL by around 60%. The issue is not whether the biology works. It does.
The issue has been adoption. Injectables, even when powerful, tend to run into the messier side of medicine: cost concerns, insurance friction, physician hesitation, and patient reluctance. A drug can be clinically excellent and still underused if the experience around it feels cumbersome.
Enlicitide aims to change that equation by offering the same target in a once-daily pill.
What the trial found
The phase 3 trial enrolled 2,909 adults who either had a history of a major atherosclerotic cardiovascular disease event or were at elevated risk for a first one. Most were already taking statins, but their average LDL cholesterol still sat at 96.1 mg/dL, a reminder that standard therapy, while essential, is not always enough.
“The study population reflects what we see in clinical practice,” Navar said. “Even the highest intensity statins are often not enough to get people to their cholesterol goals.”
Participants were randomly assigned to receive either enlicitide or a placebo. After 24 weeks, those taking enlicitide saw their LDL cholesterol fall by 57.1%, while the placebo group saw a slight 3.0% increase. The cholesterol-lowering effect held through 52 weeks.
The drug also improved other markers linked to cardiovascular risk, including non-HDL cholesterol, apolipoprotein B and lipoprotein(a). Just as importantly, the incidence of adverse events did not appear to differ between the groups.
“These reductions in LDL cholesterol are the most we have ever achieved with an oral drug by far since the development of statins,” Navar said.
The bigger story: convenience can be a clinical advantage. If enlicitide eventually wins regulatory approval, its most important feature may not be that it lowers LDL – we already have drugs that do that extremely well. Its importance may lie in making aggressive lipid-lowering feel more routine, more scalable and more realistic for everyday care.
That is not a trivial distinction. A pill fits more easily into primary care workflows. It fits more easily into patient habits. And in prevention, habits are often where the battle is won or lost. A medicine that is easier to prescribe, easier to take and easier to stick with can end up being more transformative than a technically superior option that never reaches enough people.
What we still do not know
This trial shows that enlicitide lowers cholesterol impressively. It has not yet been proven that it reduces heart attacks or strokes directly. That is the next and more meaningful test, and researchers are already running another trial to answer it.
Lower LDL is a strong and well-established surrogate, but the gold standard is still hard outcomes: fewer cardiovascular events, longer, healthier lives and less disability. For now, enlicitide is best viewed as a promising step, but not yet a finished revolution. Still, it is an intriguing one.
[1] https://www.nejm.org/doi/10.1056/NEJMoa2511002
[2] https://www.utsouthwestern.edu/newsroom/articles/year-2026/feb-experimental-pill-bad-cholesterol.html
